公开(公告)号：WO2006124813A2

公开(公告)日：2006-11-23

申请号：PCT/US2006018796

申请日：2006-05-16

Applicant: ABBOTT LAB ,  GRACIAS VIJAYA J ,  ABAD-ZAPATERO CELERINO ,  DJURIC STEVAN W ,  JI ZHIQIN ,  MICHAELIDES MICHAEL R ,  STEWART KENT D ,  ZANZE IRINI

Inventor： GRACIAS VIJAYA J ,  ABAD-ZAPATERO CELERINO ,  DJURIC STEVAN W ,  JI ZHIQIN ,  MICHAELIDES MICHAEL R ,  STEWART KENT D ,  ZANZE IRINI

CPC classification number: C07D487/04

Abstract: Compounds having the Formula (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Abstract translation: 具有式（I）的化合物可用于抑制蛋白酪氨酸激酶。 本发明还公开了制备化合物的方法，含有该化合物的组合物和使用该化合物的处理方法。

公开(公告)号：WO2010124042A3

公开(公告)日：2011-02-03

申请号：PCT/US2010031974

申请日：2010-04-22

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG ,  WANG YING ,  BREWER JASON T ,  AKRITOPOULOU-ZANZE IRINI ,  DJURIC STEVAN W ,  POHLKI FRAUKE ,  BRAJE WILFRIED ,  RELO ANA-LUCIA

Inventor： WANG YING ,  BREWER JASON T ,  AKRITOPOULOU-ZANZE IRINI ,  DJURIC STEVAN W ,  POHLKI FRAUKE ,  BRAJE WILFRIED ,  RELO ANA-LUCIA

IPC: C07D498/04 ,  A61K31/4985 ,  A61K31/551 ,  A61K31/553 ,  A61P25/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/04

CPC classification number: C07D498/04 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/04

Abstract: The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及1,2,3,4,4a，5,6,7-八氢吡嗪并[1,2-a] [1,4]苯并二氮杂，1,2,3,4,4a， 7-八氢吡嗪并[1,2-a] [1,5]苯并二氮杂，2,3,4,4a，5,6,7,11b-八氢-1H-吡啶并[3,4-d] [2]苯并氮杂， 1,2,3,4,4a，5,6,7-八氢吡嗪并[1,2-a] [1]苯并氮杂，1,2,3,4,4a，5-六氢-7H-吡嗪并[1,2 -a] [4,1]苯并氧氮杂和2,3,4,4a，5,6-六氢-1H-吡嗪并[2,1-d] [1,5]苯并氧氮杂和5,6,7,7a ，其中R 1，R 2，R 3，R 4，R 5，R 6，R 6，R 5，R 6， X1，X2，X3，X4，Y1，Y2和Y3如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：WO2004026822A3

公开(公告)日：2004-05-06

申请号：PCT/US0329018

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN W ,  WIEDEMAN PAUL E ,  YONG HONG ,  FEENSTRA MELISSA J ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SHAM HING L ,  STEWART KENT D ,  SZCZEPANKIEWICZ BRUCE G

IPC: A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12 ,  A61K31/401 ,  A61K31/4439 ,  A61K31/506

CPC classification number: C07D207/27 ,  C07D207/16 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R ,R and R have the definitions given in the description.

Abstract translation: 本发明涉及抑制二肽基肽酶IV（DPP-IV）的式I化合物，其可用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖症，X综合征，高胰岛素血症，肥胖症，动脉粥样硬化和 各种免疫调节疾病。 或其药学上可接受的盐或前药，其中X，R，R 1，R 2和R 3具有说明书中给出的定义。

公开(公告)号：WO0218354A8

公开(公告)日：2002-07-04

申请号：PCT/US0126883

申请日：2001-08-29

Applicant: ABBOTT LAB

Inventor： WIEDEMAN PAUL E ,  DJURIC STEVAN W ,  PLIUSHCHEV MARINA ,  SCIOTTI RICHARD J ,  MADAR DAVID J ,  KOPECKA HANA

IPC: A61P31/04 ,  C07D263/20 ,  C07D413/10 ,  C07D417/10 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/506

CPC classification number: C07D263/20 ,  C07D413/10 ,  C07D417/10

Abstract: Compounds of forumula (I) or therapeutically acceptable salts or prodrugs thereof, are useful for treating bacterial infections, psoriasis, arthritis, and toxicity due to chemotherapy. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

Abstract translation: （I）或其治疗上可接受的盐或前药的化合物可用于治疗细菌感染，牛皮癣，关节炎和由于化疗引起的毒性。 公开了化合物的制备，含有该化合物的组合物以及使用该化合物治疗疾病。

公开(公告)号：CA2608974C

公开(公告)日：2014-03-18

申请号：CA2608974

申请日：2006-05-16

Applicant: ABBOTT LAB

Inventor： GRACIAS VIJAYA J ,  ABAD-ZAPATERO CELERINO ,  DJURIC STEVAN W ,  JI ZHIQIN ,  MICHAELIDES MICHAEL R ,  STEWART KENT D ,  ZANZE IRINI

IPC: C07D487/04 ,  A61K31/551 ,  A61P35/00

Abstract: Compounds having the Formula (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

公开(公告)号：ES2423668T3

公开(公告)日：2013-09-23

申请号：ES10720502

申请日：2010-05-20

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG ,  ABBVIE INC

Inventor： WELCH DENNIE S ,  AKRITOPOULOU-ZANZE IRINI ,  BRAJE WILFRIED ,  DJURIC STEVAN W ,  WILSON NOEL S ,  TURNER SEAN C ,  KRUGER ALBERT W ,  RELO ANA-LUCIA ,  SHEKHAR SHASHANK ,  ZHAO HONGYU ,  GANDARILLA JORGE ,  GASIECKI ALAN F ,  LI HUANQIU ,  THOMPSON CHRISTINA M ,  ZHANG MIN

IPC: C07D487/04 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61P25/00 ,  C07D491/04 ,  C07D495/04

Abstract: Un compuesto de fórmula (I):**Fórmula** o una sal farmacéuticamente aceptable del mismo,donde A está seleccionado entre el grupo que consiste en R1, R3, R4, y R5 están seleccionados independientemente entre el grupo que consiste en hidrógeno, alquenilo, alquilo, haloalquilo, G1, G2, -(CR4aR5a)m-G1, y -(CR4aR5a)m-G2; R4a y R5a, en cada caso, cada uno es independientemente hidrógeno, halógeno, alquilo, o haloalquilo; G1, en cada caso, es independientemente arilo o heteroarilo, donde cada G1 está independientemente sin sustituir osustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados entre el grupo que consiste en alquilo, alquenilo, alquinilo,halógeno, ciano, -NO2, -OR1b, -OC(O)R1b, -OC(O)N(Rb)(R3b), -SR1b, -S(O)R2b, -S(O)2R2b, -S(O)2N(Rb)(R3b), -C(O)R1b,-C(O)OR1b, -C(O)N(Rb)(R3b), -N(Rb)(R3b), -N(Ra)C(O)R1b, -N(Ra)C(O)O(R1b), -N(Ra)C(O)N(Rb)(R3b), -(CR4bR5b)m-NO2,-N(Rb)S(O)2(R2b), -(CR4bR5b)m-OR1b, -C(OH)[(CR4bR5b)m-R4b]2, -(CR4bR5b)m-OC(O)R1b, -(CR4bR5b)m-OC(O)N(Rb)(R3b), -(CR4bR5b)m-SR1b, -(CR4bR5b)m-S(O)R2b, -(CR4bR5b)m-S(O)2R2b, -(CR4bR5b)m-S(O)2N(Rb)(R3b),-(CR4bR5b)m-C(O)R1b, -(CR4bR5b)m-C(O)OR1b, -(CR4bR5b)m-C(O)N(Rb)(R3b), -(CR4bR5b)m-N(Rb)(R3b), -(CR4bR5b)m-N(Ra)C(O)R1b, -(CR4bR5b)m-N(Ra)C(O)O(R1b), -(CR4bR5b)m-N(Ra)C(O)N(Rb)(R3b), -(CR4bR5b)m-N(Rb)S(O)2(R2b),cianoalquilo, y haloalquilo.

公开(公告)号：SG182187A1

公开(公告)日：2012-07-30

申请号：SG2012043113

申请日：2008-06-04

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： AKRITOPOULOU-ZANZE IRINI ,  WAKEFIELD BRIAN D ,  MACK HELMUT ,  TURNER SEAN C ,  GASIECKI ALAN F ,  GRACIAS VIJAYA J ,  SARRIS KATHY ,  KALVIN DOUGLAS M ,  MICHMERHUIZEN MELISSA J ,  SHUAI QI ,  PATEL JYOTI R ,  BAKKER MARGARETHA ,  TEUSCH NICOLE ,  KOVAR PETER J ,  DJURIC STEVAN W ,  LONG ANDREW J ,  VASUDEVAN ANIL ,  HOBSON ADRIAN ,  ST JOHN MOORE NIGEL ,  WANG LU ,  GEORGE DAWN ,  LI BIQIN ,  FRANK KRISTINE ,  JOHNSON ERIC T

Abstract: 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORSAbstractThe present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein A, R1,R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Ala, PAK4, PLK, CK2, KDR, MK2, JNK I, aurora, pim I and nek 2.No suitable figure

公开(公告)号：CA2759607A1

公开(公告)日：2010-10-28

申请号：CA2759607

申请日：2010-04-22

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： WANG YING ,  BREWER JASON T ,  AKRITOPOULOU-ZANZE IRINI ,  DJURIC STEVAN W ,  POHLKI FRAUKE ,  BRAJE WILFRIED ,  RELO ANA-LUCIA

IPC: C07D498/04 ,  A61K31/4985 ,  A61K31/551 ,  A61K31/553 ,  A61P25/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D491/04

Abstract: The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：DE60315336T2

公开(公告)日：2008-05-08

申请号：DE60315336

申请日：2003-09-15

Applicant: ABBOTT LAB

Inventor： MADAR DAVID ,  PEI ZHONGHUA ,  PIREH DAISY ,  DJURIC STEVAN W ,  WIEDEMAN PAUL E ,  YONG HONG ,  MICHMERHUIZEN MELISSA J ,  KOPECKA HANA ,  LI XIAOFENG ,  LONGENECKER KENTON ,  SHAM HING L ,  STEWART KENT D ,  SZCZEPANKIEWICZ BRUCE G

IPC: C07D207/00 ,  A61P37/02 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention relates to compounds of formula I which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases. Or pharmaceutically acceptable salts or prodrugs thereof, wherein X,R,R ,R and R have the definitions given in the description.

公开(公告)号：MXPA06010904A

公开(公告)日：2007-06-11

申请号：MXPA06010904

申请日：2005-03-24

Applicant: ABBOTT LAB

Inventor： MICHAELIDES MICHAEL R ,  HOLMS JAMES H ,  STEINMAN DOUGLAS H ,  MUCKEY MELANIE A ,  WADA CAROL K ,  ARNOLD LEE D ,  DINGES JURGEN ,  DIXON RICHARD W ,  DJURIC STEVAN W ,  ERICSSON ANNA M ,  FISCHER KIMBA ,  GASIECKI ALAN F ,  GRACIAS VIJAYA J ,  RAFFERTY PAUL ,  XIA ZHIREN ,  AKRITOPOULOU-ZANZE IRINI ,  ZHANG HENRY Q ,  TAKESHITA MAKOTO

IPC: C07D409/04 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/5377 ,  A61P35/00 ,  A61P37/00 ,  C07D231/54 ,  C07D409/14 ,  C07D413/14 ,  C07D491/04 ,  C07D495/04

Abstract: Se utilizan los compuestos de la presente invencion para inhibir proteinas de tirosin-cinasas. Tambien se describen los metodos para hacer los compuestos, composiciones que los contienen y metodos de tratamiento utilizando los compuestos.